Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 12/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961377 | 0.96 | TP53 (0.49) | TRPM8TP53POLBMAPTCYP1A2 | |
| SCHEMBL3963030 | 0.92 | TRPM8 (0.64) | TRPM8NPC1RAB9A | |
| SCHEMBL3960808 | 0.90 | MEN1 (0.48) | TRPM8TP53POLBMAPTRAB9A | |
| SCHEMBL3956898 | 0.90 | TP53 (0.52) | TRPM8TP53POLBMAPTNPC1 | |
| SCHEMBL3965747 | 0.89 | TRPM8 (0.48) | TRPM8TP53POLBMAPTCYP1A2 | |
| SCHEMBL3964680 | 0.89 | TRPM8 (0.52) | TRPM8TP53MAPTNPC1RAB9A | |
| SCHEMBL3959704 | 0.88 | TRPM8 (0.51) | TRPM8NPC1RAB9A | |
| SCHEMBL3963575 | 0.88 | TRPM8 (0.58) | TRPM8NPC1RAB9A | |
| SCHEMBL3963788 | 0.83 | TRPM8 (0.52) | TRPM8TP53MAPTRAB9A | |
| SCHEMBL3961874 | 0.82 | TP53 (0.50) | TRPM8TP53MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-7462644-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050131068-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131068-A1 | Therapeutic agents | GPR119, INSR, LIPA | TRPM8 4238/4885TP53 2284/4885POLB 3744/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | TRPM8 4071/4885TP53 4725/4885POLB 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.